Skip to main content

Table 1 Characteristics of the patients included in the analysis

From: Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

 ControlsMSAPDVaPPD/VaPDp valuea
N25MSA-PMSA-CMSA-P/C4497 
1121
14    
Age (at inclusion)64.5 ± 10.361.1 ± 8.057.9 ± 9.969.5 ± 9.070.2 ± 5.10.003
Sex (male/female)11/149/528/167/26/10.004
Disease duration since first symptoms (months)N.A.38.9 ± 38.342.0 ± 34.325.5 ± 16.1141.0 ± 19.80.556
Disease Severity (baseline)
 HY scoreN.A.2.7 ± 0.8 (14)2.0 ± 0.6 (43)2.9 ± 0.7 (9)2.6 ± 0.9 (7)0.001
 UPDRS-III scoreN.A.30.3 ± 10.0 (14)28.2 ± 13.8 (42)33.1 ± 11.3 (9)40.1 ± 16.8 (7)0.203
 ICARS scoreN.A.10.9 ± 11.5 (11)2.8 ± 3.4 (39)10.7 ± 5.1 (7)8.8 ± 6.1 (6)0.000
 MMSE scoreN.A.27.9 ± 2.7 (13)28.2 ± 2.1 (44)26.7 ± 2.9 (8)26.4 ± 1.5 (7)0.030
Disease Severity (3 years follow-up)
 HY scoreN.A.4.0 ± 1.1 (10)2.3 ± 0.8 (41)4.2 ± 1.0 (6)2.8 ± 0.9 (5)0.000
 UPDRS-III scoreN.A.33.8 ± 6.8 (5)29.9 ± 15.1 (39)44.7 ± 9.3 (4)39.2 ± 20.6 (5)0.109
 ICARS scoreN.A.16.0 ± 17.9 (5)3.5 ± 3.2 (35)20.0 ± 5.7 (4)5.0 ± 2.5 (5)0.001
 MMSE scoreN.A.27.4 ± 1.1 (5)27.9 ± 2.9 (34)27.0 ± 4.1 (4)24.8 ± 5.7 (5)0.189
Survival after 12 years (dead/alive)N.A.13/111/339/04/3 
  1. Data are represented as mean ± SD (N). p value was considered significant when < 0.05, MSA multiple system atrophy, PD Parkinson’s disease, VaP vascular parkinsonism, PD/VaP PD with overlapping VaP, MSA-P multiple system atrophy parkinsonian type, MSA-C multiple system atrophy cerebellar type, MSA-P/C multiple system atrophy mixed parkinsonian and cerebellar, N.A not applicable, HY Hoehn and Yahr, UPDRS-III Unified Parkinson’s Disease Rating Scale part III (motor score), ICARS International Cooperative Ataxia Rating Scale, MMSE Mini-Mental State Examination. aKruskal-Wallis test with Bonferroni correction and Chi-square for sex differences